DUBLIN–(BUSINESS WIRE)–The “In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022” report has been added to ResearchAndMarkets.com’s offering.
The Asia Pacific (APAC) region is a fast-growing in vitro diagnostics (IVD) market, which is witnessing increasing focus by leading global players in the market. Southeast Asia has been identified as one of the key regions in APAC region offering significant opportunities for IVD companies.
This report focuses on three IVD markets in Southeast Asia: Malaysia, Indonesia, and Singapore. These three countries together represent a fast-growing geographic region offering significant opportunity for IVD companies. The total population of these three countries is over 310 million, which is close to the population in the United States.
Among these three countries, Singapore has established world class healthcare service capabilities in terms of infrastructure as well as skilled manpower. Though the population is less than 6 million, the Singapore market is attractive for IVD companies and it has become a medical tourism hub in the region.
Indonesia, on the other hand, is a country with a huge population of about 275 million people. The country is taking significant steps to improve its healthcare infrastructure, which is offering considerable opportunities for IVD companies. The Malaysian market, with a population of about 32 million falls in between these two countries, both in terms of healthcare service capabilities and growth potentials.
In Vitro Diagnostics (IVD) in Malaysia, Singapore, and Indonesia, 2022 covers the following segments:
- POC
- Clinical Chemistry
- Immunoassays
- Molecular Assays
- Hematology
- Coagulation
- Microbiology and Virology
- Blood Testing and Typing
- Histology and Cytology
The report also profiles key companies in the market:
- Abbott Diagnostics
- ARKRAY
- Beckman Coulter, Inc. / Danaher
- Becton, Dickinson, and Company (BD)
- BioCytech Corporation
- bioMerieux Inc.
- Bio-Rad Laboratories, Inc.
- Caris Life Sciences
- Cephei
- CTK Biotech Inc
- Danaher Corporation
- Dexcom
- DiaSorin S.p.A
- Grifols S.A.
- Healgen Scientific LLC
- Hologic, Inc.
- Horiba Medical
- Lucence Diagnostics
- Medical Innovation Ventures Sdn. Bhd. (Mediven)
- Mindray (Shenzhen Mindray Bio-medical Electronics Co., Ltd.)
- MiRXES Pte Ltd.
- OraSure Technologies, Inc.
- Ortho Clinical Diagnostics (Ortho)
- PerkinElmer, Inc. (PE)
- QIAGEN
- Reszon Diagnostics International
- Roche Diagnostics
- Sysmex Corporation
- Vela Diagnostics
- Veredus Laboratories Pte Ltd
Key Topics Covered:
Chapter 1: Executive Summary
Chapter 2: COVID-19 Testing Market Trends
Chapter 3: Point-of-Care Tests
Chapter 4: Core Lab and Clinical Chemistry
Chapter 5: Immunoassays
Chapter 6: Molecular Assays
Chapter 7: Hematology
Chapter 8: Coagulation
Chapter 9: Microbiology and Virology
Chapter 10: Blood Banking Services
Chapter 11: Histology and Cytology
Chapter 12: Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/a33wbm
The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
